Home / Health / Cancer Breakthrough: Stanford's 20-Year Therapy Approved
Cancer Breakthrough: Stanford's 20-Year Therapy Approved
8 Oct
Summary
- Stanford's Orca-T therapy received FDA approval in June 2026.
- 78% of patients on Orca-T were free of GVHD one year post-transplant.
- First commercial patient treated at Stanford for high-risk leukemia.
Stanford researchers announced a major milestone for their blood-cancer treatment, Orca-T, following U.S. FDA approval in June 2026. This therapy, developed over two decades, has now treated its first commercial patient at Stanford Medicine.
The approval was based on a phase 3 trial demonstrating that 78% of patients receiving Orca-T were free from moderate-to-severe graft-versus-host disease (GVHD) one year post-transplant. This figure sharply contrasts with the 38.4% observed in patients undergoing standard transplantation.
Orca-T addresses the critical challenge in stem cell transplants: balancing the donor immune system's role in fighting cancer against the risk of GVHD, where donor cells attack the patient's tissues. The treatment employs a sequenced administration of different cell types, including regulatory T cells (Tregs), to control immune responses.
Stanford stated Tregzi, the approved form of Orca-T, is the first Treg cell-based immunotherapy cleared by the FDA for clinical use. Researchers continue to explore Orca-T's potential in other patient groups and in combination with other therapies.
